Driving Success Across the
Pharmaceutical Industry
Senior regulatory and quality leadership from first-in-human to last year on market — molecule to market, and every year after.
Senior regulatory and quality leadership from first-in-human to last year on market — molecule to market, and every year after.
A molecule survives a decade of development by passing through hands: nonclinical to clinical, clinical to CMC, submission to review, approval to the commercial floor. Every handoff is a place where a program loses months — a meeting that wasn't asked the right question, a specification that CMC and regulatory read differently, a site that met the filing but not the inspection. We put senior regulatory and quality leaders inside pharmaceutical companies at exactly those seams: fractional executives and program leads who have carried drugs across each one before, from emerging biotech-scale programs to established commercial portfolios.
Our service lines map to the drug lifecycle — each phase below links to the practices doing that work, led by people who have done it inside pharma companies, not alongside them.
Every handoff between phases is a place a program quietly loses a year. We staff the seams.
The program takes shape: nonclinical strategy that answers the questions FDA will ask, a pre-IND meeting run to a decision, and an IND assembled to open clean.
Trials that hold up later: GCP quality systems sized to the program, vendor oversight that actually oversees, and CMC maturing on the same clock as the data.
The NDA or BLA itself: submission strategy, medical writing, labeling negotiated with intent, and eCTD publishing that never becomes the critical path.
The weeks that decide the year: pre-approval inspection readiness, launch-quality systems on the commercial line, and promotional review from day one.
The longest phase, managed like it matters: post-approval changes, variations across markets, and a quality system that ages better than the patent.
The companies that move fastest through this climate treat it as strategy, not weather. These are the four fronts we're helping pharmaceutical clients work today.
A reorganized FDA, Annex 1, nitrosamines, availability as a quality duty. Strategy, not weather.
Restructuring and turnover have made review interactions less predictable — which makes every formal meeting, and every written question, worth preparing like it's the only one you'll get.
The revised Annex 1 made Contamination Control Strategy a named document with teeth. Sterile and aseptic operations are being read against it in both EU and FDA inspections.
Nitrosamine assessments are now standing obligations, and data integrity remains the thread inspectors pull first. Both punish programs that treated them as one-time exercises.
ICH Q9(R1) put product availability inside quality risk management. Shortage-prone products need supply risk assessed with the same rigor as safety — regulators now expect to see it.
A senior-level regulatory or quality executive, embedded in your organization for a fraction of the cost of the hire — and none of the recruiting timeline.
A defined scope with a defined finish line — delivered by the same senior people, not handed down to a junior team.
Our practitioners have led programs across the forms and filing routes that define modern pharma.
Life sciences is all we do, and pharmaceutical work is where most of us grew up: in the submission war rooms, the pre-approval inspections, and the post-approval years that decide whether a product stays on the market.
Our people have held the Head of Regulatory and Head of Quality seats inside pharma companies. Advice reads differently when the person giving it has signed the form.
Hundreds of FDA meetings, submissions, and inspections between us — we know how the current agency actually behaves, not how it behaved five years ago.
A three-person virtual company and a global commercial portfolio need different machinery. We've built both and don't confuse the two.
The leader you meet in the first call is the one who does the work. That's the entire model.
From FDA meeting strategy to ICH Q12 lifecycle management, each service line has its own senior practice — built for pharmaceutical, biotech, medical device, and combination product companies.
A pre-IND question, a filing year, a warning letter, a portfolio that needs a quality system to grow into — bring us the stage and the stakes. We'll respond within one business day, and all inquiries are strictly confidential.
